13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001943819
Total reported value
$300.5M
$300.5M
56 檔
61.9%
In Q3 2024, Valence8 US LP's U.S. equity holdings reached a combined market value of $300.5M, distributed across 56 disclosed stock positions.
In Q3 2024, Valence8 US LP displayed an active expansion posture, initiating 41 new positions and adding to 3 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including QUAL, QQQ, IQLT) accounted for 61.9% of total reported equity market value during Q3 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | QUAL | Ishares Msci USA Quality Fac | ETF-Other | 25.10% | +7.47% | +12.10% | |
| 2 | QQQ | Invesco Qqq Trust Series 1 | ETF-Tech | 17.84% | +5.34% | +14.91% | |
| 3 | IQLT | Ishares Msci International Q | ETF-Other | 17.66% | -4.97% | +15.03% | |
| 4 | EFV | Ishares Msci Eafe Value ETF | ETF-Other | 9.53% | -2.98% | — | |
| 5 | VTV | Vanguard Value ETF | ETF-Other | 7.00% | +2.89% | -3.37% | |
| 6 | XLP | Ss Consumer Staples Sel Sect | ETF-Other | 5.69% | +2.69% | -1.80% | |
| 7 | EWU | Ishares Msci United Kingdom | ETF-Other | 3.25% | -0.05% | -3.50% | |
| 8 | EWJ | Ishares Msci Japan ETF | ETF-Other | 3.22% | — | — | |
| 9 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 2.07% | — | — | |
| 10 | XLU | St Sr Utl Sl Se Spdr Etf-usd | ETF-Other | 1.74% | +1.07% | -6.56% | |
| 11 | AMGN | Amgen Inc | Stock-Healthcare | 0.53% | — | — | |
| 12 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.47% | — | — | |
| 13 | INSM | Insmed Inc | Stock-Healthcare | 0.44% | — | — | |
| 14 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 0.41% | — | — | |
| 15 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 0.38% | — | — | |
| 16 | ASND | Ascendis Pharma A/S | Stock-Other | 0.28% | — | — | |
| 17 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.26% | — | — | |
| 18 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 0.26% | — | — | |
| 19 | INDV | Indivior Pharmaceuticals, Inc. | Stock-Other | 0.23% | — | — | |
| 20 | LLY | Eli Lilly & Co | Stock-Healthcare | 0.23% | — | — | |
| 21 | ARGX | Argenx Se - Adr | Stock-Healthcare | 0.21% | — | — | |
| 22 | KROS | Keros Therapeutics Inc | Stock-Other | 0.19% | — | — | |
| 23 | NVO | Novo-nordisk A/s-spons Adr | Stock-Healthcare | 0.19% | — | — | |
| 24 | JANX | Janux Therapeutics Inc | Stock-Other | 0.19% | — | — | |
| 25 | NUVL | Nuvalent Inc-a | Stock-Other | 0.17% | — | — | |
| 26 | FLNA | Filana Therapeutics Inc | Stock-Other | 0.17% | — | — | |
| 27 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 0.16% | — | — | |
| 28 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 0.14% | — | — | |
| 29 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.14% | — | — | |
| 30 | TYRA | Tyra Biosciences Inc | Stock-Other | 0.13% | — | — | |
| 31 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.13% | — | — | |
| 32 | ALT | Altimmune Inc | Stock-Other | 0.13% | — | — | |
| 33 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.12% | — | — | |
| 34 | PCVX | Vaxcyte Inc | Stock-Other | 0.12% | — | — | |
| 35 | MRNA | Moderna Inc | Stock-Healthcare | 0.11% | — | — | |
| 36 | NTLA | Intellia Therapeutics Inc | Stock-Other | 0.11% | — | — | |
| 37 | VIR | Vir Biotechnology Inc | Stock-Other | 0.10% | — | — | |
| 38 | 2655787D | Blueprint Medicines CORP | Stock-Other | 0.10% | — | — | |
| 39 | CLDX | Celldex Therapeutics Inc | Stock-Other | 0.09% | — | — | |
| 40 | ENTA | Enanta Pharmaceuticals Inc | Stock-Other | 0.09% | — | — | |
| 41 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.08% | — | — | |
| 42 | APLT | Applied Therapeutics Inc | Stock-Other | 0.07% | — | — | |
| 43 | ZVRA | Zevra Therapeutics Inc | Stock-Other | 0.06% | — | — | |
| 44 | ERAS | Erasca Inc | Stock-Other | 0.05% | — | — | |
| 45 | IOVA | Iovance Biotherapeutics Inc | Stock-Other | 0.05% | — | — | |
| 46 | SLDB | Solid Biosciences Inc | Stock-Other | 0.05% | — | — | |
| 47 | VTGN | Vistagen Therapeutics Inc | Stock-Other | 0.04% | — | — | |
| 48 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 0.04% | — | — | |
| 49 | ✓ | Zura Bio LTD | Stock-Other | 0.03% | — | — | |
| 50 | ALEC | Alector Inc | Stock-Other | 0.03% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | AZNN | Astrazeneca Plc-spons Adr | +2.1% | NEW | New buy |
| 2 | AMGN | Amgen Inc | +0.5% | NEW | New buy |
| 3 | SLNOEUR | Soleno Therapeutics Inc | +0.5% | NEW | New buy |
| 4 | INSM | Insmed Inc | +0.4% | NEW | New buy |
| 5 | JAZZ | Jazz Pharmaceuticals plc | +0.4% | NEW | New buy |
| 6 | BMY | Bristol-myers Squibb Co | +0.4% | NEW | New buy |
| 7 | ASND | Ascendis Pharma A/S | +0.3% | NEW | New buy |
| 8 | RARE | Ultragenyx Pharmaceutical In | +0.3% | NEW | New buy |
| 9 | CRSP | CRISPR Therapeutics AG | +0.3% | NEW | New buy |
| 10 | INDV | Indivior Pharmaceuticals, Inc. | +0.2% | NEW | New buy |
| 11 | LLY | Eli Lilly & Co | +0.2% | NEW | New buy |
| 12 | ARGX | Argenx Se - Adr | +0.2% | NEW | New buy |
| 13 | KROS | Keros Therapeutics Inc | +0.2% | NEW | New buy |
| 14 | NVO | Novo-nordisk A/s-spons Adr | +0.2% | NEW | New buy |
| 15 | JANX | Janux Therapeutics Inc | +0.2% | NEW | New buy |
| 16 | NUVL | Nuvalent Inc-a | +0.2% | NEW | New buy |
| 17 | FLNA | Filana Therapeutics Inc | +0.2% | NEW | New buy |
| 18 | APLSUSD | Apellis Pharmaceuticals Inc | +0.2% | NEW | New buy |
| 19 | ✓ | Avadel Pharmaceuticals PLC ADR | +0.1% | NEW | New buy |
| 20 | CRNX | Crinetics Pharmaceuticals In | +0.1% | NEW | New buy |
| 21 | TYRA | Tyra Biosciences Inc | +0.1% | NEW | New buy |
| 22 | APGE | Apogee Therapeutics Inc | +0.1% | NEW | New buy |
| 23 | ALT | Altimmune Inc | +0.1% | NEW | New buy |
| 24 | VRDN | Viridian Therapeutics Inc | +0.1% | NEW | New buy |
| 25 | PCVX | Vaxcyte Inc | +0.1% | NEW | New buy |
| 26 | MRNA | Moderna Inc | +0.1% | NEW | New buy |
| 27 | NTLA | Intellia Therapeutics Inc | +0.1% | NEW | New buy |
| 28 | VIR | Vir Biotechnology Inc | +0.1% | NEW | New buy |
| 29 | 2655787D | Blueprint Medicines CORP | +0.1% | NEW | New buy |
| 30 | CLDX | Celldex Therapeutics Inc | +0.1% | NEW | New buy |
| 31 | ENTA | Enanta Pharmaceuticals Inc | +0.1% | NEW | New buy |
| 32 | RLAY | Relay Therapeutics Inc | +0.1% | NEW | New buy |
| 33 | APLT | Applied Therapeutics Inc | +0.1% | NEW | New buy |
| 34 | ZVRA | Zevra Therapeutics Inc | +0.1% | NEW | New buy |
| 35 | ERAS | Erasca Inc | +0.1% | NEW | New buy |
| 36 | IOVA | Iovance Biotherapeutics Inc | +0.1% | NEW | New buy |
| 37 | SLDB | Solid Biosciences Inc | +0.1% | NEW | New buy |
| 38 | VTGN | Vistagen Therapeutics Inc | 0% | NEW | New buy |
| 39 | BCRX | Biocryst Pharmaceuticals Inc | 0% | NEW | New buy |
| 40 | ✓ | Zura Bio LTD | 0% | NEW | New buy |
| 41 | ALEC | Alector Inc | 0% | NEW | New buy |
| 42 | XLU | St Sr Utl Sl Se Spdr Etf-usd | -0.2% | -6.56% | Trim |
| 43 | IQLT | Ishares Msci International Q | -0.5% | +15.03% | Add |
| 44 | EWJ | Ishares Msci Japan ETF | -0.6% | — | Unchanged |
| 45 | EWU | Ishares Msci United Kingdom | -0.7% | -3.50% | Trim |
| 46 | XLP | Ss Consumer Staples Sel Sect | -1% | -1.80% | Trim |
| 47 | QQQ | Invesco Qqq Trust Series 1 | -1.3% | +14.91% | Add |
| 48 | VTV | Vanguard Value ETF | -1.4% | -3.37% | Trim |
| 49 | EFV | Ishares Msci Eafe Value ETF | -1.5% | — | Unchanged |
| 50 | QUAL | Ishares Msci USA Quality Fac | -1.7% | +12.10% | Add |
According to official SEC Form 13F filings, Valence8 US LP reported a total U.S. public equity portfolio value of $300.5M across 56 disclosed positions in Q3 2024.
During Q3 2024, Valence8 US LP's top holdings by market value included QUAL (25.1%)、QQQ (17.8%)、IQLT (17.7%). The largest single position, QUAL, represented 25.1% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
AZNN
市值: $5.0M
Top Position Liquidated / Trimmed
VTV
前期市值: $16.0M
In Q3 2024, Valence8 US LP made 48 total portfolio adjustments, initiating 41 new buys, adding to 3 positions, trimming 4 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.